Basecamp Research raises $140M Series C, backed by NVIDIA, Anthropic and NATO Innovation Fund, to advance AI-designed cell therapies
The London biotech's oversubscribed round will fund next-generation AI models and a therapeutic pipeline targeting cancer and autoimmune disease.
Seven years after its founders had to persuade investors just to fund a genetic database, Basecamp Research has closed a $140 million Series C. The London-based AI drug company now has a therapeutic pipeline that puts its flagship AI model to its first real clinical test.
The oversubscribed round, announced September 23, 2026, was led by S32 and drew participation from NVIDIA, Anthropic's Anthology Fund, the NATO Innovation Fund, The Rockefeller Foundation, King Philanthropies, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Redalpine, Singular, Sovereign AI, True Ventures and others.
We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how. AI-based approaches promise to change what's possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.— Glen Gowers, co-founder and CEO, Basecamp Research
Reprogramming a patient's cells from within the body — rather than removing, engineering and returning them — is the core approach Basecamp is pursuing with in vivo cell therapy. Basecamp argues that current cell therapies are doubly constrained: they are limited in the biological complexity they can deliver, and they depend on manufacturing that costs hundreds of thousands of dollars per patient. Its answer is EDEN, a 28-billion-parameter biological foundation model trained on the company's proprietary Trillion Gene Atlas.
EDEN stands for environmentally-derived evolutionary network. Unlike AI systems built for a single scientific task, EDEN is designed to recognize patterns across a broad range of biology — the company describes its goal as a universal understanding of how DNA works across all of life. Paired with large serine recombinases that can precisely integrate DNA sequences into the genome, the platform is meant to make cell therapies more sophisticated and customizable while being simpler to administer.
The Trillion Gene Atlas, which sits at the center of the platform, is described by Basecamp as the world's largest proprietary biological AI training dataset. Developed alongside NVIDIA, Anthropic, PacBio and Ultima Genomics, the atlas draws its biological data from access and benefit-sharing partnerships spanning more than 30 countries on all seven continents. Basecamp puts the dataset's contents at more than 100 billion novel genes and over 100 trillion tokens, including 10 billion genes previously unknown to science drawn from 1 million newly discovered species — a collection the company says is more than ten times the size of all public genomic resources combined.
The pipeline spans gene insertion, gene editing and peptide design, with early focus on cancer and autoimmune disease. Across multiple modalities, Basecamp says its preclinical results have been strong. According to a preprint dated January 12 and posted to bioRxiv — with co-authors from NVIDIA, Basecamp, Microsoft and two research institutions — EDEN returned a 63.2% overall functional hit rate across varied DNA prompts when supplied with just 30 base pairs of DNA drawn from outside its training data. Half of EDEN-generated large serine recombinases were active in human cells, reaching therapeutically relevant levels of CAR insertion in primary human T-cells.
Turning to antibiotics — a distinct application of the same underlying models — Basecamp said that work conducted with a University of Pennsylvania team led by César de la Fuente found 97% of EDEN-designed antibiotic peptides to be active against WHO priority pathogens in laboratory testing. Without any subsequent optimization or iterative engineering, a compound called EDEN-7 performed within the same efficacy range as a last-line antibiotic when tested in mice carrying multidrug-resistant Acinetobacter baumannii infections, the company said.
The financing will be used for three things: training a new generation of EDEN models, advancing the therapeutic pipeline toward clinical development, and expanding pharmaceutical partnerships. To lead that last effort, Basecamp appointed Richard Pearce — formerly Biogen's head of business development, strategy and portfolio management — as Chief Business Officer.
Andy Conrad, General Partner at lead investor S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors as part of the deal.
AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people's lives. Basecamp Research is building an important technology platform at the center of that opportunity.— Andy Conrad, General Partner, S32
André Hoffmann, Vice-Chairman of Roche, is among the individual investors; he also serves as a board member of Roche subsidiary Genentech and as co-chair of the World Economic Forum.
The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.— André Hoffmann, Vice-Chairman, Roche
Anthropic's involvement runs deeper than a check. Basecamp added EDEN's antibiotic design and vaccine target prediction models to Claude Science — Anthropic's AI research workbench for life sciences — on June 30, 2026, putting them within reach of users across Claude.ai, Claude Desktop, Claude Mobile, Claude Code and other Anthropic products. Anthropic's investment came through the Menlo Anthology Fund — a $100 million fund launched in 2024 in partnership with Menlo Ventures — which also gives portfolio companies access to Anthropic products and research credits.
London is home to Basecamp's headquarters, with additional offices and laboratories in Cambridge, Massachusetts. The company was co-founded by Glen Gowers and Oliver Vince. Its next milestones are advancing the pipeline from preclinical into clinical development and training the next generation of EDEN models — the two tasks the new capital is explicitly earmarked to fund.
Why it matters — If EDEN's preclinical results translate to the clinic, Basecamp's approach could make cell therapies for cancer and autoimmune disease far cheaper and more complex to engineer — a significant shift in a field where manufacturing alone can cost hundreds of thousands of dollars per patient.
⚠ Not yet confirmed
- Anthropic's investment came specifically through the Menlo Anthology Fund, a $100 million fund financed by Menlo Ventures in partnership with Anthropic
- $800M valuation claim
- total funding $225 million
- "according to Reuters"
- "six-program" pipeline specificity and Endpoints attribution
- specific April appointment timing for Pearce
Reported by reuters.com, prnewswire.com, unite.ai, endpoints.news, genengnews.com
- Andre HoffmannGerman footballer